Moxetumomab Pasudotox Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of moxetumomab pasudotox during breastfeeding. Because moxetumomab is a large protein molecule with a molecular weight of about 63,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Pasudotox is a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential anti-cancer activity that may enter milk. Until more data become available, moxetumomab pasudotox should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Moxetumomab Pasudotox
CAS Registry Number
1020748-57-5
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Antineoplastic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
